HDC Releases First SVM-Based Image Analysis iPhone App for Melanoma Risk Assessment
|
HDC Receives Prestigious MICO Award from MDB Capital Group LLC
|
| Health Discovery Corporation (OTCBB: HDVY), a molecular diagnostics company that uses patent protected advanced mathematical techniques for personalized medicine, places its vast expertise in the palms of health-conscious consumers with the launch of its first iPhone app called MelApp. This new iPhone App for Melanoma Risk Assessment is designed to help users learn about melanoma and identify areas on their skin which may need attention from a physician specializing in the diagnosis of melanoma. MelApp can assist in the early detection of melanoma with the goal of ultimately saving lives. Read full Press Release |
 |
|
Health Discovery Corporation announced that they have received the prestigious MICO Award presented by MDB Capital Group at its invitation-only Bright Lights Conference held May 11-12, 2010
Read full Press Release
|
|
HDC Partners With NYC Pancreatic Cancer Center to Develop Molecular Diagnostic Test
|
Health Discovery Corp Licenses New Prostate Cancer Test to Abbott
|
Health Discovery Corporation announced that the Company has entered into an exclusive agreement with the Pancreas, Biliary and Liver Surgery Center of New York at Saint Vincent Catholic Medical Centers in New York City to develop new molecular diagnostic tests for the early detection of pancreatic cancer. The Pancreas, Biliary and Liver Surgery Center is under the leadership of Drs. Michael Wayne, Franklin Kassim and Avrim Cooperman
Read full Press Release |
Health Discovery Corporation announced that it has entered into an agreement with Abbott (NYSE: ABT) to commercialize HDC’s new molecular diagnostics gene-based tests for clinically significant prostate cancer. Abbott has acquired co-exclusive clinical laboratory rights and exclusive in vitro diagnostic rights for commercialization of HDC’s tissue-based prostate cancer test as well as HDC’s urine-based prostate cancer test.
Read full Press Release
|
HDC Licenses Biomarkers for Urine-Based Prostate Cancer Test to Quest Diagnostics
|
Clarient Launches Gene Expression Test for Prostate Cancer
|
|
Health Discovery Corporation, a molecular diagnostics company, today announced that it has licensed rights to develop a new urine-based test for clinically significant prostate cancer to Quest Diagnostics Incorporated (NYSE: DGX) , the world’s leading provider of diagnostic testing, information and services. Under the terms of the agreement, HDC will receive payments, royalties and additional undisclosed financial considerations.
Read full Press Release
|
Gene Profile Discovered By Health Discovery Corporation Will Provide Molecular Confirmation of Gleason Grade 3 and 4 Cancer Cells in Prostate Biopsies
Clarient, Inc. (Nasdaq: CLRT), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists, and the pharmaceutical industry, today announced the commercial launch of its new gene expression test for prostate cancer. This new test will be available through Clarient’s PATHSiTE(TM) virtual reporting tool and accessible to the company’s entire pathology network.
Read full Press Release
|
| HDC Signs Deal to Develop Breast Cancer Test |
HDC' Licenses SVM Technology to Pfizer |
|
Smart Personalized Medicine, LLC, Founded by Dr. Richard Caruso, Chairman of Integra Life Sciences (NasdaqGS: IART), Signs Agreement with Health Discovery Corporation to Develop New Breast Cancer Prognostic Test.
Health Discovery Corporation to Receive a Fifteen Percent Equity Position in Smart Personalized Medicine, LLC and Will Receive Royalties Paid on a Per Test Basis from Breast Cancer Prognostic Tests Performed.
Read full Press Release
|
Health Discovery Corporation Announces Worldwide License Agreement With Pfizer.
Health Discovery Corporation announces a license agreement with Pfizer Inc. (NYSE:PFE). Under the terms of the agreement, Pfizer may access HDC’s pattern recognition technology for use in its worldwide research and development activities. The license includes HDC’s Support Vector Machine (“SVM”), Fractal Genomic Modeling (“FGM”), and related methods for data analysis.
Read full Press Release |
| HDC's Extensive Patent Portfolio |
HDC' Successful In Patent Infringement Lawsuits |
HDC's Patent Portfolio Includes:
49 Issued Patents
39 Pending Patents
View full Patent Portfolio |
Health Discovery Corporation Settles Patent Infringement Suit against Ciphergen Biosystems, Inc.
Health Discovery Corporation announced that its patent infringement action against Ciphergen Biosystems, Inc. has been settled. Under the terms of the agreement, Ciphergen will pay $600,000 to HDC and receive a non-exclusive license to use HDC's support vector machines in applications for Ciphergen's proprietary SELDI-based technologies.
Read full Press Release
Health Discovery Corporation Obtains Consent Judgment in Patent Lawsuit Atainst Equbits LLC.
Equbits to Cease Use of HDC’s Patented SVM Technology.
Read full Press Release |
